Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib

Zhang, L; Wang, YS; Lin, LZ; Yu, YF; Lu, S

Lu, S (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Oncol, Sch Med, Shanghai 200030, Peoples R China.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023; 15 ():

Abstract

Savolitinib is a highly selective mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor (TKI). Based on its significant efficacy shown in ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索